{
    "id": 26495,
    "fullName": "YES1 amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "YES1 amplification indicates an increased number of copies of the YES1 gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 7525,
        "geneSymbol": "YES1",
        "terms": [
            "YES1",
            "c-yes",
            "HsT441",
            "P61-YES",
            "Yes"
        ]
    },
    "variant": "amp",
    "createDate": "04/27/2017",
    "updateDate": "10/02/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19877,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CH6953755 treatment inhibited viability and phosphorylation of Yes1 in an esophageal cancer cell line harboring YES1 amplification in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 31391186).",
            "molecularProfile": {
                "id": 27722,
                "profileName": "YES1 amp"
            },
            "therapy": {
                "id": 9238,
                "therapyName": "CH6953755",
                "synonyms": null
            },
            "indication": {
                "id": 5041,
                "name": "esophageal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16801,
                    "pubMedId": 31391186,
                    "title": "YES1 Is a Targetable Oncogene in Cancers Harboring YES1 Gene Amplification.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31391186"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19878,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CH6953755 treatment inhibited viability of a gastroesophageal junction adenocarcinoma cell line harboring YES1 amplification in culture (PMID: 31391186).",
            "molecularProfile": {
                "id": 27722,
                "profileName": "YES1 amp"
            },
            "therapy": {
                "id": 9238,
                "therapyName": "CH6953755",
                "synonyms": null
            },
            "indication": {
                "id": 4944,
                "name": "gastroesophageal junction adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16801,
                    "pubMedId": 31391186,
                    "title": "YES1 Is a Targetable Oncogene in Cancers Harboring YES1 Gene Amplification.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31391186"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19884,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CH6953755 treatment inhibited tumor growth in a cell line xenograft model of squamous non-small cell lung cancer harboring YES1 amplification (PMID: 31391186).",
            "molecularProfile": {
                "id": 27722,
                "profileName": "YES1 amp"
            },
            "therapy": {
                "id": 9238,
                "therapyName": "CH6953755",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16801,
                    "pubMedId": 31391186,
                    "title": "YES1 Is a Targetable Oncogene in Cancers Harboring YES1 Gene Amplification.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31391186"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19881,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) treatment inhibited viability of a gastroesophageal junction adenocarcinoma cell line harboring YES1 amplification in culture (PMID: 31391186).",
            "molecularProfile": {
                "id": 27722,
                "profileName": "YES1 amp"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4944,
                "name": "gastroesophageal junction adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16801,
                    "pubMedId": 31391186,
                    "title": "YES1 Is a Targetable Oncogene in Cancers Harboring YES1 Gene Amplification.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31391186"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19880,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) treatment inhibited viability of an esophageal cancer cell line harboring YES1 amplification in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 31391186).",
            "molecularProfile": {
                "id": 27722,
                "profileName": "YES1 amp"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5041,
                "name": "esophageal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16801,
                    "pubMedId": 31391186,
                    "title": "YES1 Is a Targetable Oncogene in Cancers Harboring YES1 Gene Amplification.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31391186"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10675,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, dasatinib (Sprycel) treatment of Her2 positive breast cancer cells with YES1 amplification and overexpression restored sensitivity to trastuzumab (Herceptin) (PMID: 28158234).",
            "molecularProfile": {
                "id": 27723,
                "profileName": "YES1 amp YES1 over exp"
            },
            "therapy": {
                "id": 5575,
                "therapyName": "Dasatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8734,
                    "pubMedId": 28158234,
                    "title": "Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28158234"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10676,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, dasatinib (Sprycel) treatment of Her2 positive breast cancer cells with YES1 amplification and overexpression restored sensitivity to lapatinib (Tykerb) (PMID: 28158234).",
            "molecularProfile": {
                "id": 27723,
                "profileName": "YES1 amp YES1 over exp"
            },
            "therapy": {
                "id": 5576,
                "therapyName": "Dasatinib + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8734,
                    "pubMedId": 28158234,
                    "title": "Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28158234"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10674,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, amplification and overexpression of Yes1 contributed to lapatinib (Tykerb) resistance in Her2 positive breast cancer cells, in culture (PMID: 28158234).",
            "molecularProfile": {
                "id": 27723,
                "profileName": "YES1 amp YES1 over exp"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8734,
                    "pubMedId": 28158234,
                    "title": "Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28158234"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10673,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, amplification and overexpression of Yes1 contributed to trastuzumab (Herceptin) resistance in Her2 positive breast cancer cells, in culture (PMID: 28158234).",
            "molecularProfile": {
                "id": 27723,
                "profileName": "YES1 amp YES1 over exp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8734,
                    "pubMedId": 28158234,
                    "title": "Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28158234"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10678,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Sprycel (dasatinib) to Tagrisso (osimertinib) therapy inhibited growth of a Tagrisso (osimertinib)-resistant lung cancer cell line harboring an EGFR exon 19 deletion and EGFR T790M with YES1 amplification and over expression in culture, and reduced tumor growth in xenograft models (PMID: 28416483).",
            "molecularProfile": {
                "id": 27724,
                "profileName": "EGFR exon 19 del EGFR T790M YES1 amp YES1 over exp"
            },
            "therapy": {
                "id": 4946,
                "therapyName": "Dasatinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11302,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acquisition of YES1 amplification in a lung cancer cell line harboring an EGFR exon 19 deletion and EGFR T790M was associated with resistance to Tagrisso (osimertinib) in culture and in xenograft models (PMID: 28416483).",
            "molecularProfile": {
                "id": 27946,
                "profileName": "EGFR exon 19 del EGFR T790M YES1 amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14159,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, amplification of YES1 was identified in post-treatment samples from lung adenocarcinoma patients harboring EGFR L858R with acquired resistance to EGFR tyrosine kinase inhibitors, including Tarceva (erlotinib) (PMID: 29875142).",
            "molecularProfile": {
                "id": 29951,
                "profileName": "EGFR L858R YES1 amp"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11478,
                    "pubMedId": 29875142,
                    "title": "YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29875142"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19883,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a gastroesophageal junction adenocarcinoma cell line harboring YES1 amplification and expressing YES1 T348I demonstrated resistance to Sprycel (dasatinib) treatment in culture (PMID: 31391186).",
            "molecularProfile": {
                "id": 34630,
                "profileName": "YES1 T348I YES1 amp"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4944,
                "name": "gastroesophageal junction adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16801,
                    "pubMedId": 31391186,
                    "title": "YES1 Is a Targetable Oncogene in Cancers Harboring YES1 Gene Amplification.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31391186"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19882,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an esophageal cancer cell line harboring YES1 amplification and expressing YES1 T348I demonstrated resistance to Sprycel (dasatinib) treatment in culture (PMID: 31391186).",
            "molecularProfile": {
                "id": 34630,
                "profileName": "YES1 T348I YES1 amp"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5041,
                "name": "esophageal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16801,
                    "pubMedId": 31391186,
                    "title": "YES1 Is a Targetable Oncogene in Cancers Harboring YES1 Gene Amplification.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31391186"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19879,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a gastroesophageal junction adenocarcinoma cell line harboring YES1 amplification and expressing YES1 T348I demonstrated resistance to CH6953755 treatment in culture (PMID: 31391186).",
            "molecularProfile": {
                "id": 34630,
                "profileName": "YES1 T348I YES1 amp"
            },
            "therapy": {
                "id": 9238,
                "therapyName": "CH6953755",
                "synonyms": null
            },
            "indication": {
                "id": 4944,
                "name": "gastroesophageal junction adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16801,
                    "pubMedId": 31391186,
                    "title": "YES1 Is a Targetable Oncogene in Cancers Harboring YES1 Gene Amplification.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31391186"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19876,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an esophageal cancer cell line harboring YES1 amplification and expressing YES1 T348I demonstrated resistance to CH6953755 treatment in culture (PMID: 31391186).",
            "molecularProfile": {
                "id": 34630,
                "profileName": "YES1 T348I YES1 amp"
            },
            "therapy": {
                "id": 9238,
                "therapyName": "CH6953755",
                "synonyms": null
            },
            "indication": {
                "id": 5041,
                "name": "esophageal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16801,
                    "pubMedId": 31391186,
                    "title": "YES1 Is a Targetable Oncogene in Cancers Harboring YES1 Gene Amplification.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31391186"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27722,
            "profileName": "YES1 amp",
            "profileTreatmentApproaches": [
                {
                    "id": 11306,
                    "name": "Dasatinib",
                    "profileName": "YES1 amp"
                }
            ]
        },
        {
            "id": 27723,
            "profileName": "YES1 amp YES1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27724,
            "profileName": "EGFR exon 19 del EGFR T790M YES1 amp YES1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27946,
            "profileName": "EGFR exon 19 del EGFR T790M YES1 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29951,
            "profileName": "EGFR L858R YES1 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34630,
            "profileName": "YES1 T348I YES1 amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}